Apyx Medical Study Shows Up to 81.8% Cellulite Improvement with Combined Avéli and Renuvion
summarizeSummary
Apyx Medical published clinical data showing up to 81.8% cellulite improvement in patients treated with a combined Avéli and Renuvion procedure. This study, involving 22 patients, documented measurable reductions in dimple volume, surface area, and depth, with some cases achieving complete resolution. This specific, strong efficacy data for a combined treatment using two of Apyx's key aesthetic products provides more detail than earlier reports today and could significantly boost market adoption and sales. It adds to the company's recent positive momentum, including strong financial results and expanded FDA clearances.
At the time of this announcement, APYX was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $178M. The 52-week trading range was $1.38 to $4.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.